{"id":1013363,"date":"2026-10-26T07:30:36","date_gmt":"2026-10-26T11:30:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/"},"modified":"2026-10-26T07:30:36","modified_gmt":"2026-10-26T11:30:36","slug":"natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/","title":{"rendered":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122<\/b><\/p>\n<p class=\"bwalignc\"><i>Analyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD)<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.natera.com&amp;esheet=54628116&amp;newsitemid=20261026646022&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=4e7c601913b22f175f7e3bf8830e0541\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera\u2019s genetic test for CKD.<\/p>\n<p>\nAmong the key findings were data from a large, real-world database of patients with indicators of kidney disease.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOne such analysis revealed significant delays in diagnosing and managing CKD. Among patients with incident CKD, the median time from the first abnormal kidney indicator to a documented diagnosis was about 5.3 years, with median eGFR falling from 75 to 66 mL\/min\/1.73 m\u00b2 in the two years before diagnosis.<\/p>\n<\/li>\n<li>\nAnother analysis highlighted gaps in referrals for specialist care. Of patients meeting KDIGO-aligned high-risk criteria, only one third had any documented nephrology care, and those who did waited a median of 149 days. Furthermore, just 26.6% of high-risk patients with hereditary or structural kidney disease had documented nephrology care, the lowest of any high-risk group.<\/p>\n<\/li>\n<\/ul>\n<p>\n\u201cThese findings underscore the need for earlier etiologic evaluation. Renasight genetic testing is designed to address this need by clarifying the cause of kidney disease and supporting earlier, more targeted specialist referrals,\u201d said Sangeeta Bhorade, MD, Chief Medical Officer, Organ Health, Natera. \u201cRenasight is an essential tool in CKD management, which we believe should be a standard part of care for patients with signs of the disease.\u201d<\/p>\n<p><b>Full list of presentations at ASN Kidney Week 2026 included:<\/b><\/p>\n<p><b>Abstract TH-PO0128<br \/>\n<br \/><\/b>Presenter: Emily Hendricks, MS, CGC<br \/>\n<br \/><i>Evidence of Reduced Penetrance in Complement Gene-Positive Patients from a Large Renal Cohort<\/i><\/p>\n<p><b>Abstract TH-PO0125<br \/>\n<br \/><\/b>Presenter: Margaret Westemeyer, MS, CGC<br \/>\n<br \/><i>A Broad Panel as the Perfect Complement: Unexpected Genetic Findings in Patients at Risk for Complement-Mediated Disease<\/i><\/p>\n<p><b>Abstract TH-PO0134<br \/>\n<br \/><\/b>Presenter: Nicholas Case, MS, CGC<br \/>\n<br \/><i>Functional Kidney Disease Predominates in PTPN11-Associated Noonan Syndrome Identified Through Nephrology Practice<\/i><\/p>\n<p><b>Abstract TH-PO0564<br \/>\n<br \/><\/b>Presenter: Darbey Raible, MS, CGC<br \/>\n<br \/><i>Genetic Ancestry as a Lens on ESKD Risk<\/i><\/p>\n<p><b>Abstract TH-PO0558<br \/>\n<br \/><\/b>Presenter: Ronen Schneider, MD<br \/>\n<br \/><i>Most Patients with KDIGO-Aligned High-Risk Kidney Disease Do Not Receive Nephrology Care: A Real-World Analysis<\/i><\/p>\n<p><b>Abstract TH-PO0200<br \/>\n<br \/><\/b>Presenter: Emily Hendricks, MS, CGC<br \/>\n<br \/><i>Unexpectedly Mild Adult-Onset ADPKD in Patients with Digenic Hypomorphic PKD1 and Truncating PKD2 Variants<\/i><\/p>\n<p><b>Abstract 4558577<br \/>\n<br \/><\/b>Presenter: Uma Arora, PhD<br \/>\n<br \/><i>Genetic Diagnoses Across Clinical Presentations of Glomerular Diseases<\/i><\/p>\n<p><b>Abstract<\/b><b>FR-PO0507<br \/>\n<br \/><\/b>Presenter: Michelle Bloom, PhD<br \/>\n<br \/><i>Clinical Phenotypes and Outcomes of Cardiovascular Disease in a Real-World CKD Cohort: A Retrospective Analysis<\/i><\/p>\n<p><b>Abstract FR-PO0109<br \/>\n<br \/><\/b>Presenter: Ankit Shah, MS<br \/>\n<br \/><i>Real-World Treatment Patterns Among Patients with APOL1-Mediated Kidney Disease (AMKD) in the United States<\/i><\/p>\n<p><b>Abstract FR-PO1200<br \/>\n<br \/><\/b>Presenter: Ruchi Naik, MD, PhD<br \/>\n<br \/><i>Elevated Donor-Derived Cell-Free DNA in Recurrent Lupus Nephritis After Kidney Transplantation: A Case Report<\/i><\/p>\n<p><b>Abstract FR-OR078<br \/>\n<br \/><\/b>Presenter: Fredrik Erlandsson, MD, PhD<br \/>\n<br \/><i>Global Mutational Landscape in COL4A3, COL4A4, and COL4A5 and Estimating the Alport Syndrome (AS) Population<\/i><\/p>\n<p><b>Abstract 4555599<br \/>\n<br \/><\/b>Presenter: Shirlee Shril, MS<br \/>\n<br \/><i>Diagnostic Inertia in CKD: Delayed Recognition of Abnormal Kidney Biomarkers in a Large Real-World Electronic Health Record Cohort<\/i><\/p>\n<p><b>Abstract SA-PO0171<br \/>\n<br \/><\/b>Presenter: Tessa Pitman, MS, CGC<br \/>\n<br \/><i>From Early Stones to Silent Disease: Phenotypic Extremes in Individuals with Homozygous HOGA1 Variants<\/i><\/p>\n<p><b>Abstract SA-PO0191<br \/>\n<br \/><\/b>Presenter: Akash Anand, M.S., CGC<br \/>\n<br \/><i>Rare Identification of HbS\/Hb Crete in a Patient Undergoing Pretransplant Kidney Genetic Testing<\/i><\/p>\n<p><b>Abstract SA-PO0182<br \/>\n<br \/><\/b>Presenter: Margaret Westemeyer, M.S., CGC<br \/>\n<br \/><i>Implications for Donor Safety and Family Risk Assessment After Unexpected CLCN5-Related Dent Disease in Living Donor Evaluation<\/i><\/p>\n<p><b>Abstract SA-PO0190<br \/>\n<br \/><\/b>Presenter: Mary Conway, M.S., CGC<br \/>\n<br \/><i>Unrecognized Nephrogenic Syndrome of Inappropriate Antidiuresis in a Symptomatic Female Patient with an Activating AVPR2 Variant<\/i><\/p>\n<p><b>Abstract SA-PO0120<br \/>\n<br \/><\/b>Presenter: Fadi Yacoub, M.D., Mercy Medical Center<br \/>\n<br \/><i>Novel NEK8 Variant Associated with Adult-Onset ADPKD<\/i><\/p>\n<p><b>Abstract SA-PO0925<br \/>\n<br \/><\/b>Presenter: Maksim Chapman<br \/>\n<br \/><i>Demographic Disparities in Time to CKD Diagnosis After Abnormal Laboratory Findings<\/i><\/p>\n<p><b>About Natera<\/b><\/p>\n<p>\nNatera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54628116&amp;newsitemid=20261026646022&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=2&amp;md5=08b5fcc87178251f686245cd3cd704df\">www.natera.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in \u201cRisk Factors\u201d in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.natera.com%2Fnews%2Fdefault.aspx&amp;esheet=54628116&amp;newsitemid=20261026646022&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=3&amp;md5=822255663fd1b523bb860f634463d728\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54628116&amp;newsitemid=20261026646022&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=d2302422b9f218a455e955b962e621cb\">www.sec.gov<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261026646022\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261026646022\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<br \/>\n<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Oncology Health Medical Devices Genetics Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261026646022\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 Analyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD) AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera\u2019s genetic test for CKD. Among the key findings were data from a large, real-world database of patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013363","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 Analyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD) AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera\u2019s genetic test for CKD. Among the key findings were data from a large, real-world database of patients with &hellip; Continue reading &quot;Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T11:30:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122\",\"datePublished\":\"2026-10-26T11:30:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/\"},\"wordCount\":1037,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/\",\"name\":\"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-26T11:30:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/","og_locale":"en_US","og_type":"article","og_title":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 - Market Newsdesk","og_description":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 Analyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD) AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera\u2019s genetic test for CKD. Among the key findings were data from a large, real-world database of patients with &hellip; Continue reading \"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-26T11:30:36+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122","datePublished":"2026-10-26T11:30:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/"},"wordCount":1037,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/","name":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-26T11:30:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026646022r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-shares-real-world-analyses-and-data-at-asn-kidney-week-2026-highlighting-the-critical-need-for-genetic-testing-with-renasight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013363"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013363\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}